Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
Speakers
Mike Doustdar
— CEO, Novo Nordisk
Summary
Novo Nordisk CEO Mike Doustdar discusses the historic launch of the Wegovy oral pill, which reached 3 million prescriptions in 22 weeks. He details the pill's efficacy advantage, peptide-based reduced drug interactions, and its appeal to new GLP-1 users who avoided injections. He also addresses investor skepticism, the Ozempic pill rebranding, and the promising CagriSema pipeline asset.
- Wegovy pill reached 1 million prescriptions in 12 weeks and 2 million more in the next 10 weeks, the best launch in history.
- The pill delivers 16.6% weight loss vs. competitor's 12.4%, a 34% relative advantage.
- As a peptide, it avoids liver metabolism, so it has fewer restrictions with birth control, statins, and other drugs.
- 70% of users are women and 80% are new to GLP-1, proving the oral format expands the market.
- CagriSema, a combination injection, showed 23% weight loss and additional cardiometabolic benefits.
- The CEO says investors are not yet rewarding the pill's success but expects recognition over time.
Ideas
Wegovy oral pill dominates obesity market.
Novo Nordisk's Wegovy pill launch is the best prescription drug launch in history, with 3 million prescriptions in just 22 weeks and accelerating uptake. The pill has a 34% efficacy advantage over the competing oral GLP-1 (16.6% vs 12.4% weight loss). Its peptide formulation avoids liver metabolism, eliminating drug–drug interactions with birth control, statins, and other common medications, which is a key advantage for the 70% female customer base. 80% of Wegovy pill users are GLP-1-naïve, demonstrating that the oral format is massively expanding the addressable obesity market by converting needle-averse patients. Additionally, the next-generation pipeline asset CagriSema (semaglutide + amylin analog) delivers 23% weight loss and additive cardiometabolic benefits, providing another growth layer. The CEO believes the market is currently not giving credit for this success and that patient execution will eventually be reflected in the stock.
Up Next
This CNBC video, published June 09, 2026, features Mike Doustdar discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: Mike Doustdar · Tickers: NVO